Research programme: platelet aggregation inhibitors - Astellas/Portola PharmaceuticalsAlternative Names: Platelet adhesion inhibitors research programme - Astellas/Portola Pharmaceuticals
Latest Information Update: 29 Mar 2010
At a glance
- Originator Astellas Pharma
- Mechanism of Action Platelet aggregation inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Vascular disorders
Most Recent Events
- 14 Jun 2005 Preclinical trials in Vascular disorders in USA (unspecified route)